Immunovant, Inc. (IMVT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in New York City, NY, United States. The current CEO is Eric Venker.
IMVT has IPO date of 2019-06-21, 362 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.4B.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies to treat autoimmune diseases. The company's lead candidate, batoclimab, is a fully human monoclonal antibody that selectively inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials recently initiated for warm autoimmune hemolytic anemia. Founded in 2018 and headquartered in New York, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
